Seaport Therapeutics, Inc. (SPTX) fair value analysis
Nasdaq · Updated 2026-10-19
SPTX price how computed
Valuation status
No fair-value estimate yetSPTX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for SPTX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $17.83
- Sector
- Healthcare
- 12-month range
- $17.13–$23.61
- Market cap
- $954M
- From 52-week high
- -24.5%
- Shares outstanding
- 53.5M
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Seaport Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for neurological and psychiatric disorders. The company operates in the United States within the healthcare sector.
Fundamentals (3 quarters) how computed
- Market cap
- $954M
- Shares outstanding
- 53.5M
Derived indicators how computed
- 52-week position
- The bottom quarter of its range
Earnings how computed
- Next earnings report
- 2026-11-02
- Last 2 quarters vs consensus
- 0 beat, 2 missed
- Quarter by quarter
- 2026-06 ▼ miss (-150.7%)
2026-03 ▼ miss (-166.5%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 1 hold · 0 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $38.3
- Target vs last price
- +114.8%
What our data shows for SPTX
- Shares are trading in the lower third of their 12-month price range of $17.13–$23.61.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- SPTX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the SPTX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is SPTX stock undervalued?
TickrTrends has no fair-value estimate for SPTX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is SPTX's TickrTrends verdict?
SPTX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
Is SPTX overbought or oversold?
TickrTrends does not currently publish an RSI signal for SPTX.
When does SPTX report earnings next?
SPTX's next earnings report is scheduled for 2026-11-02, per the published earnings calendar.
Does SPTX usually beat earnings estimates?
Over its last 2 reported quarters SPTX beat the consensus estimate 0 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about SPTX?
Of 8 analysts covering SPTX, 7 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $38.3 (+114.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.